Dendrimers are highly branched, nanoscale polymers being investigated as carriers that may help some drugs cross the gastrointestinal lining after swallowing. Studies describe movement between gut-lining cells and through the cells themselves, but transport depends on the dendrimer’s design and experimental model. This remains an investigational approach, not an established way to improve absorption in people.
What dendrimers do in an oral drug formulation
A dendrimer is a branched polymer with many surface groups that can be changed or used to associate with drug molecules. Researchers have studied poly(amidoamine), or PAMAM, dendrimers particularly extensively for oral delivery. A drug may be carried as a complex, in which it associates with the dendrimer, or as a conjugate, in which it is chemically attached. These approaches are being explored for drugs with poor oral-delivery properties; they do not mean that every drug can be made absorbable by adding a dendrimer. Liu, Tee and Chiu’s review of PAMAM dendrimers in oral delivery describes these carrier approaches.
As an Amazon Associate I earn from qualifying purchases.
How a dendrimer may cross the gut lining
The intestinal epithelium is a layer of cells that separates the gut contents from the body. PAMAM research describes two broad routes across that layer. The routes can occur in experimental systems, but their contribution depends on the formulation and model; neither route alone demonstrates safe, effective absorption in humans.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitches| Route | What it means | What the research suggests |
|---|---|---|
| Paracellular | Movement through spaces between epithelial cells, where tight junctions help regulate passage. | Some dendrimer chemistries may affect tight-junction integrity and alter passage between cells. Sadekar and Ghandehari’s review discusses transepithelial transport and toxicity. |
| Transcellular | Uptake into and movement through epithelial cells, including processes such as endocytosis. | Experimental studies describe cellular uptake and passage through cells; results depend on dendrimer properties and the model used. The PAMAM transport review examines these mechanisms. |
Improving passage is not automatically beneficial. If a formulation changes the epithelial barrier, that change may affect toxicity as well as transport. Findings from a cell or other experimental model should therefore not be treated as proof that a formulation safely increases absorption after oral dosing in people.
#1 Best Overall
Which formulation choices can change transport
There is no single dendrimer design established as best for oral delivery. The properties researchers vary include generation (a measure of the dendrimer’s branching structure), surface charge and chemistry, and the way the drug is loaded. Each choice can affect cellular uptake, movement across the epithelium, and toxicity. A review by Liu, Tee and Chiu discusses oral-delivery explorations, toxicity concerns, and strategies for improvement.
- Surface charge and chemistry: Cationic (positively charged) dendrimers raise gastrointestinal toxicity concerns. Neutral or negatively charged surface ligands, including PEG, have been explored as ways to reduce potential toxicity. These are investigated strategies, not universal safety guarantees.
- Efflux: Surface modification has also been discussed in relation to P-glycoprotein, a transporter involved in moving some substances out of cells. A proposed change to efflux does not by itself establish a clinically useful or safe formulation.
- Drug loading: Complexation and chemical conjugation are distinct ways to associate a drug with a dendrimer. Which approach is suitable depends on the drug and formulation; the available reviews do not establish one as generally preferable.
- Other formulation formats: A pharmacokinetics-focused review discusses dendrimer delivery in approaches including matrix tablets, lipid nanostructures, and chitosan-anchored dendrimers. These are formulation approaches, not evidence that one format consistently outperforms the others. The review’s PubMed record summarizes the oral pharmacokinetics literature.
What the evidence does—and does not—show
A 2019 pharmacokinetics-focused review reports that studies have shown improved oral bioavailability for some drugs with poor biopharmaceutical properties when delivered using dendrimer-based carriers. It does not establish a single effect size that applies across drugs or formulations. The review also calls for further in-vivo studies to clarify how dendrimer properties relate to oral pharmacokinetics. A bioavailability figure for a particular drug would need to be tied to the underlying study, formulation, and conditions rather than generalized to dendrimers as a class. See the 2019 review record.
Rank #2
- Used Book in Good Condition
The cited publications are reviews, not a complete, current audit of regulatory approvals or clinical trials. They support describing oral dendrimers as a research area, but do not establish that an oral dendrimer medicine is approved or marketed. A 2017 critical review said that “very few dendrimers has yet gained regulatory approval for systemic administration”; that statement describes the authors’ assessment at the time and concerns systemic administration generally, not the current status of oral products specifically. The review is indexed on PubMed.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchHow to assess a proposed oral dendrimer carrier
For a specific drug, a meaningful assessment needs more than a claim that a dendrimer improves permeability. Look for evidence that connects the carrier’s design to both drug exposure and safety:
Rank #3
- Which dendrimer family and generation were tested?
- What surface charge and modifications were used?
- Was the drug complexed with or conjugated to the carrier?
- Was transport measured in cells, another experimental model, or an in-vivo pharmacokinetic study?
- Were epithelial-barrier effects and gastrointestinal toxicity assessed alongside transport?
- Does the evidence concern the same drug and formulation being proposed?
The reviewed literature does not provide a head-to-head comparison that identifies one universally preferred formulation. The answer has to be judged for the particular drug, carrier design, model, and safety evidence—not inferred from the word “dendrimer.”
Quick Recap
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
